Communiqués Bolt Biotherapeutics, Inc.

Actions

BOLT

US0977021049

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 07/06/2024			Varia. 5j.	Varia. 1 janv.
0,761 ^USD	+1,48 %		+0,57 %	-32,05 %

20/05	Bolt Biotherapeutics, Inc. annonce des changements au sein de sa direction	CI
20/05	Bolt Biotherapeutics, Inc. annonce des changements au niveau de la direction générale	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bolt Biotherapeutics, Inc. - BOLT	31/05	PR
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bolt Biotherapeutics, Inc. - BOLT	22/05	PR
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bolt Biotherapeutics, Inc. - BOLT	17/05	PR
Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization and Changes to Leadership Team	14/05	GL
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update	21/03	GL
Bolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare Conference	27/02	GL
Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®	05/12	GL
Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update	09/11	GL
Bolt Biotherapeutics to Present at Stifel 2023 Healthcare Conference	07/11	GL
Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress	23/10/23	GL
Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress	23/10/23	AQ
Bolt Biotherapeutics : Boltbody™ISAC Platform	20/10/23	PU
Bolt Biotherapeutics to Present Data at the Society for Immunotherapy of Cancer’s 2023 Annual Meeting	18/10/23	GL
Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers	17/10/23	GL
Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers	17/10/23	AQ
Bolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023	16/10/23	GL
Bolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023	16/10/23	AQ
Bolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric Cancers	28/09/23	GL
Bolt Biotherapeutics Announces Issuance of U.S. Patent Covering Dectin-2-Targeting Agonist Antibodies, Including BDC-3042	12/09/23	GL
Bolt Biotherapeutics to Participate in September Investor Conferences	05/09/23	GL

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Bolt Biotherapeutics, Inc.

Actions

BOLT

US0977021049

Communiqués

Filtres